Azenta FY 2026: Revenue $621.7M, EPS ($3.7) — 10-K Summary

Azenta reported FY 2026 revenue of $621.7M, up 4.7% YoY, but net loss widened to $166.99M due to a $149.1M goodwill impairment charge. Both segments saw revenue growth, while gross margin declined to 44.2%. The company expects $11M in annual cost savings from a restructuring plan.

Original reporting
Published Nov 19, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 9:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Azenta FY 2026: Revenue $621.7M, EPS ($3.7) — 10-K Summary — source image
Decision brief

The 30-second read

$AZTABearishMed
01

Why it matters

The headline trading relevance is the combination of revenue growth with a much wider net loss, driven by a large non-cash goodwill impairment, plus margin compression and inventory reserve pressure. The stated annualized cost savings from restructuring provides a forward-looking offset but is not quantified beyond the $11.0M target.

02

Market read

For traders, the impairment and margin/inventory drivers are the immediate sentiment catalysts, while the restructuring savings target is the main medium-term offset to monitor.

03

What to watch

Gross margin decline is attributed to fixed-cost absorption, rework costs, and excess/obsolete inventory reserves, so traders should watch whether inventory normalization and restructuring execution reverse the margin trend.

Relevance 6/10Novelty 6/10Timing: after-hours, based on a Nov. 19, 2026 10-K summary

Background

The piece summarizes Azenta’s FY 2026 results from its Nov. 19, 2026 10-K, including segment revenue changes and a Multiomics restructuring plan.

Company-level read

Ticker impact

$AZTABearishMedium confidence
Context

Azenta reports FY 2026 revenue of $621.7M (+4.7% YoY) and a widened net loss driven by a $149.1M non-cash goodwill impairment charge.

Expected impact

Likely downside bias as investors focus on the large goodwill impairment and margin compression, with some stabilization if cost-savings execution is credible.

Evidence & confidence

The article’s key incremental datapoints are the impairment charge, net loss/EPS deterioration, gross margin decline, and the stated annualized cost-savings target from the Multiomics restructuring plan.

Market effects

Signals ongoing profitability pressure and balance-sheet write-down risk in life-science tools and services, with restructuring as the primary lever.

Limited direct regional spillover; mainly affects US-listed life-science services sentiment.

Modest, as the disclosed drivers are company-specific (impairment, inventory reserves, restructuring) rather than a global demand shock.

Counterpoint

The impairment is non-cash, so the market may overreact if operating cash generation and restructuring savings offset the accounting hit.

Key entities

  • Azenta, Inc.

    US-listed life-science tools and services provider reporting FY 2026 revenue growth, a large goodwill impairment, and a Multiomics restructuring cost-savings plan.

Related articles

$AZTAHigh

Why Azenta Stock Crushed it on Wednesday

Azenta (AZTA) stock surged 21% after reporting Q4 2026 revenue of $167M, up 5% YoY, and adjusted earnings of $0.28 per share, exceeding estimates. The company guided FY2027 revenue to $648M-$660M with margin expansion. Azenta focuses on automated sample storage for healthcare.

$AZTAHigh

Azenta (AZTA) Q4 2026 Earnings Call Transcript

Azenta (AZTA) reported Q4 2026 revenue slightly better than expected, with double-digit growth in Sample Repository Services and Consumables & Instruments. The company aims for profitable revenue growth in 2027, with initiatives in commercial expansion and new product launches. Fiscal 2026 saw 2% organic revenue growth and an adjusted EBITDA margin of 9.4%.

$AZTAMedAI 8/10

What Azenta (AZTA) Said on Its Q4 Earnings Call

Azenta (AZTA) reported Q4 revenue growth of 9% in Sample Management Solutions and flat revenue in Multiomics. The company expects 3-4% organic revenue growth in Q1 and improved free cash flow by 25% in fiscal 2026. Automated Stores faced challenges but is expected to return to modest growth. Azenta made acquisitions in gene synthesis and plans restructuring for cost savings.